The Clinical Characteristics of the Patients With Choledocholithiasis Without Cholangitis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

44 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-10-02

Study Completion Date

2013-10-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Laboratory change induced by common bile duct (CBD) stone is in general observed as the higher elevation of alkaline phosphatase (ALP) and gamma-glutamyl transpeptideas (ɤ-GT), in comparison to those of aspartate aminotransferase (AST) and alanine aminotransferase (ALT). However, some patients with CBD stone show the marked increased level of aminotransferase, which sometimes leads to misdiagnose those as liver disease caused by viral hepatitis, ischemia, and drug toxicity. The aim of this study is to investigate the clinicopathologic features of patients with CBD stones with the high level of aminotransferase in serum.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Risk Factors for Recurrence of Primary Bile Duct Stones

NCT02144493

Common Bile Duct Stones

UNKNOWN

The Comparisons of One-stage Stone Removal in Mild and Moderate Cholangitis

NCT03754491

Cholangitis; Choledocholithiasis

COMPLETED NA

Common Bile Duct Stone Management: What Have we Learned?

NCT02155244

Common Bile Duct Stones

COMPLETED

Comparison of LCBDE vs ERCP + LC for Choledocholithiasis

NCT02515474

Choledocholithiasis

COMPLETED NA

Recurrent Extrahepatic Bile Duct Stones as a Late Complication of ERCP in Patients With Coexisting Intra- and Extrahepatic Bile Duct Stones

NCT06041113

Intrahepatic Bile Duct Stone Choledocholithiasis

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Choledocholithiasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

gallstone hepatitis group,

gallstone hepatitis group (Among patients diagnosed as CBD stone who displayed above 400 IU/L of aminotransferase without cholangitis),

No interventions assigned to this group

control group

control group (Among patients diagnosed as CBD stone who showed the normal value of aminotransferase)

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. patients were diagnosed with CBD stone under endoscopic retrograde cholangiopancreatography (ERCP)
2. patients showing above 400 IU/L of aminotransferase when at the first admitted into hospital and the control groups is the patients displaying normal AST and ALT.